New hospital-led organisation aims to tackle drug pricing problem by manufacturing generic drugs

pharmafile | October 9, 2018 | News story | Manufacturing and Production PhRMA, aha, generics, hospitals, non profit, non-profit, pharma 

Seven organisations representing around 500 US hospitals have become the governing members of a newly established initiative aimed at reducing the price of drugs. The non-profit organisation Civica Rx aims to acts as an alternative to big pharma by producing generic versions of costly drugs.

The initiative has come as the furore continues surrounding drug pricing in the United States. While Donald Trump blamed Pfizer and Others, the hospitals were later dragged into the kerfuffle as the powerful pharmaceutical trade lobby PhRMA blamed them for reaping massive profits on life saving medicines.

However in what could be seen as the hospitals pushing back in retaliation, Civica Rx threatens to significantly reduce the price of drugs. Civica Rx has chosen 14 FDA approved generic drugs as their initial focus which they aim to either directly manufacture or sub-contract the manufacture of to reputable CROs. The initiative aims to have its first products on the market by 2019.

Bringing more than 35 years of industry experience to the role, the initiative named former Amgen Chief Quality Officer Martin VanTrieste as their CEO. Furthermore the experienced industry professional has agreed to lead the organisation without compensation.

“We are creating a public asset with a mission to ensure that essential generic medications are accessible and affordable,” said VanTrieste. “The fact that a third of the country’s hospitals have either expressed interest or committed to participate with Civica Rx shows a great need for this initiative. This will improve the situation for patients by bringing much needed competition to the generic drug market.”

Notably research indicates that in many instance the price of generic drugs could be reduced dramatically which would thus save patients and healthcare systems millions each year.

Louis Goss

Related Content

Pfizer sign

Delayed Pfizer vaccine dose gives 3.5 times more immunity, study shows

The Pfizer-BioNTech COVID-19 vaccine is around three and a half times more effective when dosed …

Amgen flag

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial

AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …

India report record number of COVID deaths as bodies drift down Ganges

India yesterday reported the country’s highest COVID-19 death total for a single day, with 4,205 …

Latest content